Can Al Help Risk-Stratify Your Prostate Cancer Based on Your Biopsy Slides?

Learn during this free webinar about medically proven use of AI to better stratify patient's risk and, as a result, to help in selecting a treatment approach for Prostate Cancer Patients.

This free Zoom webinar will be presented on:

April 11 at 9 AM PT (12:00 PM ET)

by Jonathan D. Tward, MD, PhD, the lead author of a paper in which a Multi Modal Artificial Intelligence (MMAI) model uses a patient's clinical data (Gleason grade group, T-stage, PSA) plus the patient's digitized biopsy slides to estimate their risk of metastasis. The discussion will be moderated by Matthew Cooperberg, MD, MPH from UCSF.

The paper compares the MMAI's estimate to the commonly used risk stratification based on Gleason Grade Group, percent of cores with cancer, PSA and T-Stage.

The model appears to improve risk stratification compared to other, commonly used models.

Reference: "Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning with Digital Histopathology."

To register for this webinar, use this link:

https://ucsf.zoom.us/webinar/register/WN_lqGB-kErRqiOxm7y1ma07w#/registration

Learn more about the Prostate Cancer Journal Club for Patients